First experience with enteric-coated mycophenolate sodium (Myfortic®) in severe recalcitrant adult atopic dermatitis: An open label study

British Journal of Dermatology

Volumn 160, Issue 3, 2009, Pages 687-691

  Van Velsen, S G A ^a   Haeck, I M ^a   Bruijnzeel Koomen, C A F M ^a   De Bruin Weller, M S ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Atopic dermatitis; Enteric coated mycophenolate sodium

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; IMMUNOGLOBULIN E; MYCOPHENOLIC ACID; PREDNISONE;

ABDOMINAL DISCOMFORT; ADULT; ADVERSE DRUG REACTION; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FLATULENCE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOMAGNESEMIA; IMMUNOGLOBULIN BLOOD LEVEL; LABORATORY TEST; MALE; MYALGIA; NAUSEA; NEPHROTOXICITY; PHOTOTHERAPY; PRIORITY JOURNAL; THYMUS; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; BIOLOGICAL MARKERS; DERMATITIS, ATOPIC; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SEVERITY OF ILLNESS INDEX; TABLETS, ENTERIC-COATED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 60449102100     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08978.x     Document Type: Article

References (24)

1. Kay J, Gawkrodger DJ, Mortimer MJ et al. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol 1994 30 : 35 9.
2. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002 96 : 23 43.
3. Berth-Jones J, Graham-Brown RA, Marks R et al. Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Br J Dermatol 1997 136 : 76 81.
4. Sowden JM, Berth-Jones J, Ross JS et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991 338 : 137 40.
5. Hijnen DJ, ten Berge O, Timmer-de Mik L et al. Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis. J Eur Acad Dermatol Venereol 2007 21 : 85 9.
6. Hijnen DJ, Knol E, Bruijnzeel-Koomen C et al. Cyclosporin A treatment is associated with increased serum immunoglobulin E levels in a subgroup of atopic dermatitis patients. Dermatitis 2007 18 : 163 5.
7. Grundmann-Kollmann M, Podda M, Ochsendorf F et al. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol 2001 137 : 870 3.
8. Murray ML, Cohen JB. Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. Clin Exp Dermatol 2007 32 : 23 7.
9. Neuber K, Schwartz I, Itschert G et al. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol 2000 143 : 385 91.
10. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 2001 24 : 645 63.
11. Behrend M, Braun F. Enteric-coated mycophenolate sodium: tolerability profile compared with mycophenolate mofetil. Drugs 2005 65 : 1037 50.
12. Budde K, Curtis J, Knoll G et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004 4 : 237 43.
13. Salvadori M, Holzer H, de Mattos A et al. the ERL B301 Study Groups. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004 4 : 231 6.
14. Kitchin JE, Pomeranz MK, Pak G et al. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol 1997 37 : 445 9.
15. Bentley R. Mycophenolic acid: a one hundred year odyssey from antibiotic to immunosuppressant. Chem Rev 2000 100 : 3801 26.
16. Hanifin J, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereal (Stockh) 1980 92 (Suppl. 44 7.
17. Budde K, Bauer S, Hambach P et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant 2007 7 : 888 98.
18. Kunz B, Oranje AP, Labreze L et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997 195 : 10 19.
19. Charman C, Williams H. The use of corticosteroids and corticosteroid phobia in atopic dermatitis. Clin Dermatol 2003 21 : 193 200.
20. Hijnen D, De Bruin-Weller M, Oosting B et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol 2004 113 : 334 40.
21. Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema-a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007 21 : 606 19.
22. Calvo N, Sanchez-Fructuoso AI, Conesa J et al. Renal transplant patients with gastrointestinal intolerability to mycophenolate mofetil: conversion to enteric-coated mycophenolate sodium. Transplant Proc 2006 38 : 2396 7.
23. Grundmann-Kollmann M, Korting HC, Behrens S et al. Successful treatment of severe refractory atopic dermatitis with mycophenolate mofetil. Br J Dermatol 1999 141 : 175 6.
24. Legendre C, Cohen D, Zeier M et al. Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studies. Transplant Proc 2007 39 : 1386 91.